NanoCarrier Announces the Opening of a US Subsidiary as Part of Its Global Expansion Plans and the Hiring of a Managing Director

NanoCarrier Co., Ltd., (the “Company”), a leading developer of nanotechnology drug delivery system with its own clinical stage drug development programs, announced that it had opened a US office as part of its global expansion plan. NanoCarrier US was established, to promote business activities outside of Japan. Based in Medford Massachusetts, NanoCarrier US will promote the Company’s technology, create more visibility, conduct market research, establish business relationships and marketing activities.

Dr. Sonke Svenson, who has vast and extensive experience in the biotechnology industry in the US and Europe, has joined the company as the Managing Director of the US office and will be in charge of promoting its activities. Dr. Svenson received his Ph.D. in organic chemistry from the Free University in Berlin, Germany. He was engaged in drug delivery research and development projects in the US at Purdue University, Northwestern University, and Princeton University, with funding from NSF, NIH, and industry. For the last 17 years, Dr. Svenson has held leadership positions in research and development related to drug delivery systems and cancer nanomedicines at several companies, including The Dow Chemical Company and Cerulean Pharma Inc. He has organized multiple international symposia on cancer nanotechnology and edited four books on drug delivery. Dr. Svenson has (co)authored 40+ peer-reviewed publications and book chapters, and given 45+ presentations at international symposia. He is a co-inventor on 14 patents and patent applications on drug delivery technologies and particle engineering

Dr. Ichiro Nakatomi, Nanocarrier’s CEO stated: “We are excited to take this step in order to establish our company as a global leader. Dr. Svenson is a great addition to our growing team and we look forward to working together to achieve our goals in and outside of Japan” 

About NanoCarrier

NanoCarrier Co., Ltd. is a clinical stage Nanomedicine company focusing on oncology drugs. The company has a robust R&D pipeline developed by its proprietary platform. The company has 4 drug candidates with 10 clinical trials being conducted globally including phase III studies. As a pioneer of micellar nanoparticles technology, the company sees as its mission to harness its proprietary technology to further the development of its drug for better treatment for oncology patients. The company is also conducting research in ADCM and RNAi as well as develop a cosmetic application using its technology.

(Code No. 4571 Tokyo Stock Exchange Mothers Section)

Press Contact:
Tetsuhito Matsuyama,
CFO and Director of CEO’s Office
Tel: +81-3-3241-0553

Source: NanoCarrier US